February 4, 2019
Company name: Mitsubishi Tanabe Pharma Corporation
Representative:Masayuki Mitsuka,President and Representative Director

Code number:4508, First Section, Tokyo Stock Exchange

Contact:

Yoshifumi Mifune, Vice President,
Head of Corporate Communications Department(TEL: +81-6-6205-5211)

Notice Regarding Conclusion of Stock Transfer Agreement
for Tanabe Seiyaku Yoshiki Factory Co., Ltd.

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President &Representative Director: Masayuki Mitsuka; hereinafter “MTPC”) concluded a stocktransfer agreement on January 31 with Nipro Pharma Corporation (Head Office: Chuoku, Osaka; President & Representative Director: Kenichi Nishida; hereinafter, “NiproPharma”). Under this agreement, MTPC’s consolidated subsidiary Tanabe Seiyaku
Yoshiki Factory Co., Ltd. (Head Office: Hida, Gifu Prefecture; President & Representative
Director: Kenji Yogo; hereinafter, “Tanabe Seiyaku Yoshiki Factory”), will be transferredto Nipro Pharma.
1. Reason for transfer
In accordance with the concept of “Reforming Operational Productivity,” which is one of
the strategic priorities under the Medium-Term Management Plan 16-20, MTPC isadvancing the reorganization and consolidation of production bases and technology
functions in order to convert to a flexible, efficient production system that demonstrates
strength in handling changes in the operating environment. As one part of thoseinitiatives, MTPC decided to transfer Tanabe Seiyaku Yoshiki Factory to Nipro Pharma.
Tanabe Seiyaku Yoshiki Factory was established in 1964 as a consolidated subsidiary ofMTPC. Since that time, it has developed its operations as a production base handlinghigh-mix, low-volume pharmaceutical packaging, with strengths in low-cost, flexible
operations. On the other hand, Nipro Pharma has top-class results in the domestic
market for contract manufacturing of pharmaceuticals. Nipro Pharma manufactures a-1-

diverse range of pharmaceuticals, including injections, oral preparations, and externalpreparations. MTPC believes that this transfer will lead to further development for
Tanabe Seiyaku Yoshiki Factory, which has technologies and experience cultivated overmany years of operations in pharmaceutical packaging.

2. Transfer method
On April 1, 2019, all of the shares of Tanabe Seiyaku Yoshiki Factory held by MTPC willbe transferred to Nipro Pharma.
After the transfer, Tanabe Seiyaku Yoshiki Factory will continue to handle contract
manufacturing for those MTPC products that it is currently manufacturing.

3. Amount of assignment
We don't disclose the transfer price due to the two companies of the arrangements.

4. Transfer timetable
January 31, 2019Conclusion of stock transfer agreement

April 1, 2019 (planned)

Transfer of Tanabe Seiyaku Yoshiki Factory to Nipro
Pharma

5. Overview of company to be transferred
Company name

Tanabe Seiyaku Yoshiki Factory Co., Ltd.

Head Office location

1-1-27, Furukawacho Koreshige, Hida, Gifu PrefectureRepresentative

President & Representative Director, Kenji Yogo

Capital¥400 million

Revenue¥4.5 billion (fiscal 2017)

Major line of businessPharmaceutical packaging

Number of employees

71 (as of the end of March 2018)

Shareholder

Mitsubishi Tanabe Pharma Corporation: 100%-2-6. Overview of company to receive the transfer
Company name

Nipro Pharma Corporation

Head Office location

2-2-7, Dosho-machi, Chuo-ku, Osaka

Representative

President & Representative Director, Kenichi Nishida

Capital¥8,669,470,000

Major lines of business

Manufacturing, sales, importing, and exporting of ethicalpharmaceuticals

Number of employees

2,785 (as of the end of March 2018)

7. Influence on results
There will be no effect on MTPC’s results for this fiscal year.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110-3-